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Background: To investigate the clinical utility of pretreatment plasma fibrinogen levels in malignant pleural mesothelioma (MPM)
patients.
Methods: A retrospective multicenter study was performed in histologically proven MPM patients. All fibrinogen levels were
measured at the time of diagnosis and clinical data were retrospectively collected after approval of the corresponding ethics
committees.
Results: In total, 176 MPM patients (mean age: 63.5 years±10.4 years, 38 females and 138 males) were analysed. Most patients
(n¼ 154, 87.5%) had elevated (X390mgdl 1) plasma fibrinogen levels. When patients were grouped by median fibrinogen,
patients with low level (p627mgdl 1) had significantly longer overall survival (OS) (19.1 months, confidence interval (CI) 14.5–23.7
months) when compared with those with high level (OS 8.5; CI 6.2–10.7 months). In multivariate survival analyses, fibrinogen was
found to be an independent prognostic factor (hazard ratio 1.81, CI 1.23–2.65). Most interestingly, fibrinogen (cutoff 75th
percentile per 750mgdl 1) proved to be a predictive biomarker indicating treatment benefit achieved by surgery within
multimodality therapy (interaction term: P¼ 0.034). Accordingly, only patients below the 75th percentile benefit from surgery
within multimodality therapy (31.3 vs 5.3 months OS).
Conclusions: Fibrinogen is a novel independent prognostic biomarker in MPM. Most importantly, fibrinogen predicted treatment
benefit achieved by surgery within multimodality therapy.
Malignant pleural mesothelioma (MPM) is a devastating and
treatment-resistant disease. The pathogenesis of MPM is closely
related to chronic inflammation, induced in up to 80% of all cases
by former asbestos exposure (Ostroff et al, 2012). Despite recent
advances in chemotherapy, the outcome of MPM treatment is still
disappointing and median overall survival (OS) of patients
receiving current standard chemotherapy regimens is 9–12 months
only (Vogelzang et al, 2003). More promising results have been
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achieved in MPM patients who were able to complete trimodality
treatment protocols – consisting of induction chemotherapy,
followed by macroscopic radical surgery and adjuvant radiation –,
resulting in median OS time of 29.1 months. Nevertheless, even in
this selected prospective cohort, only around 50% of the patients
completed the trimodality therapy protocol leading to the
aforementioned superior survival time, whereas the median OS
of the full study cohort was 16.8 months only (Krug et al, 2009).
Accordingly, there is an urgent need for biomarkers that can
stratify the MPM patients who are likely to benefit from certain
treatment modalities. Recently, our group demonstrated that
serum C-reactive protein levels (CRP) at the time of MPM
diagnosis predict survival benefit achieved by macroscopic radical
tumour surgery within multimodality treatment regimens
(Ghanim et al, 2012). In this study we showed, that patients with
normal CRP values at time of diagnosis receiving multimodality
therapy including surgery had a significantly better prognosis when
compared with patients with elevated serum CRP undergoing
surgery within multimodality therapy (median OS: 35.9 months vs
7.9 months) (Ghanim et al, 2012). These data suggested that other
inflammation-related markers may also be utilised as clinically
useful biomarkers for MPM patients.
Fibrinogen is an acute phase response protein, produced by the
liver in response to pro-inflammatory cytokines. Similar to CRP,
fibrinogen belongs to the positive acute phase response proteins,
characterised by its elevation during systemic inflammation
(Duvoix et al, 2013). Furthermore, fibrinogen has a central role
in the blood coagulation cascade and during wound healing
(Polterauer et al, 2009). It has also been shown that fibrinogen can
act as a biomarker in several diseases such as coronary heart
disease, chronic obstructive pulmonary disease and various types of
malignancies (Rosenson and Koenig, 2003; Polterauer et al, 2009;
Seebacher et al, 2010; Tang et al, 2010; Qiu et al, 2012; Seebacher
et al, 2012; Tanaka et al, 2012; Du et al, 2013; Duvoix et al, 2013;
Son et al, 2013). In addition, fibrinogen also has an important role
during vessel formation, and thus can promote tumour progression
by inducing neoangiogenesis (Laurens et al, 2006).
So far only one study investigated the fibrinogen levels in MPM
patients. Fibrinogen levels were found to be elevated in MPM when
compared with adenocarcinomas of the lung. Furthermore, plasma
fibrinogen levels correlated with interleukin-6 and CRP levels
(Nakano et al, 1998). However, to date, the prognostic or predictive
impacts of fibrinogen levels have not been reported in MPM
patients. Accordingly, we analysed the pretreatment plasma
fibrinogen levels of histologically verified MPM patients at the
time of diagnosis and its correlation to clinicopathological variables
and outcome.
PATIENTS AND METHODS
Patients. Clinical data of 176 histologically verified MPM patients
were analysed. Twenty-two patients were included by the LKH
Hochegg, 91 patients by the Medical University of Vienna and 63
patients by the University Hospital Center Zagreb. Finally, the data
of 150 patients were used for multivariate analyses as information
regarding tumour stage was missing in 26 patients.
Patients receiving curative resection were pathologically staged
according to the current IMIG staging system (Rusch, 1996) and
dichotomized into the groups early- vs late-stage MPM (stage I and
II were defined as early and stage III and IV as late stage of
disease). In patients receiving chemo- and/or radiotherapy or best
supportive care (BSC) only, clinical staging including CT/PET/
PET-CT was used for allocating to the late-stage and early-stage
group. The data of all patients were analysed after approval of the
local ethics committees.
Fifty-four patients (30.7%) received macroscopic radical surgery
within multimodality treatment protocols (induction chemotherapy
and surgery: n¼ 17; induction chemotherapy, surgery and radio-
therapy (trimodality treatment): n¼ 14; surgery and adjuvant
radiotherapy: n¼ 4; surgery and adjuvant chemotherapy: n¼ 5;
surgery and adjuvant chemoradiation: n¼ 4; induction chemother-
apy, surgery and adjuvant chemotherapy: n¼ 8; and induction
chemotherapy surgery and adjuvant chemoradiation: n¼ 2),
whereas 78 patients (44.3%) received chemo- and/or radiotherapy
alone (chemo alone: n¼ 58; radiation alone: n¼ 4; chemotherapy
and radiation: n¼ 16) and furthermore, 44 patients received BSC
(25%). Macroscopic complete resection (MCR) was achieved in
most cases by extrapleural pneumonectomy (EPP) (46 patients), in
five cases by pleurectomy/decortications and in three cases by wide
radical tumour resections. Chemotherapy consisted of platinum-
based doublet therapy in most of the cases both in the
multimodality therapy as well as in the chemotherapy/chemor-
adiation treatment groups.
Fibrinogen plasma levels. In all patients included in the study,
fibrinogen was measured during routine work-up to exclude
coagulation disorders or presence of acute infection before surgery
or diagnostic interventions. Only pretreatment and pre-interven-
tional fibrinogen levels were used for statistical analyses. Patients
suffering from acute infectious disease were excluded from all
analyses due to the acute phase response characteristics of
fibrinogen. For fibrinogen routine analyses, blood samples were
derived from peripheral venous punctures on the day of admission
to the hospital. Fibrinogen levels were measured according to the
Claus method as previously described (Clauss, 1957).
Statistical analysis. Median fibrinogen level of the whole-study
population (627, range 196–1200, s.e. of the mean 15.8mg dl 1)
was used to dichotomise into the high- and low-fibrinogen groups.
The association of fibrinogen and patients’ age, sex, stage of
disease, applied treatment modality and histological subtype was
investigated by the two-sided w2 test. Overall survival was defined
as time between histological MPM confirmation and date of last
follow up (censored patients) or date of death. The Kaplan–Meier
method was used for survival estimation and the log-rank test was
performed to investigate univariate impact on OS. The Cox
regression model was assessed for uni- and multivariate survival
analyses. Receiver Operating Characteristic (ROC) curve analysis
was performed to investigate the sensitivity and specificity of
fibrinogen levels and compared with CRP for predicting short-
term survival in MPM. Therefore, the median OS (13.8 months) of
the entire study population was used as cutoff point to divide the
study population into long (n¼ 47) and short-term survivors
(n¼ 49). Patients still alive but not reaching median OS were
excluded from these analyses (n¼ 17). In 63 patients, no diagnostic
CRP level was available. Accordingly, for the ROC analysis
comparing CRP with fibrinogen, 96 patients were used. All
reported P-values were given as two sided and were considered
statistically significant below 0.05. The Youden Index was
calculated as (sensitivityþ specificity) 1 for each cutoff point.
All statistical analyses were performed using the PASW Statistics
18.0 package (Predictive Analytics Software, SPSS Inc., Chicago, IL,
USA).
RESULTS
In total, 176 histologically verified MPM patients (mean age: 63.5
years±10.4 years, 38 females and 138 males) were included. Most
patients had epithelioid histological subtype (n¼ 146, 83%)
followed by biphasic (n¼ 18, 10.2%) and sarcomatoid MPM
(n¼ 12, 6.8%). For the statistical analysis, we combined the
biphasic and the sarcomatoid subtype as non-epithelioid MPM
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(n¼ 30, 17%). One hundred and thirty-one patients (87.3%) were
diagnosed as late-stage MPM (either stage III or IV), whereas only
19 patients (12.7%) were detected at the early stage (stage I and II)
of disease. In 26 patients (14.8%), information about the staging
was missing in the medical records. All patients were allocated to
the three major treatment groups: BSC (n¼ 44), chemo- and/or
radiotherapy (n¼ 78) and multimodality therapy including
surgical MCR (n¼ 54) as previously defined (Ghanim et al, 2012).
The majority (n¼ 154, 87.5%) of all analysed patients had
clinically relevant elevated (X390mg dl 1) plasma fibrinogen
levels at the time of MPM diagnosis. Fibrinogen levels were
strongly correlating with serum CRP (n¼ 113, Pearson’s correla-
tion coefficient: 0.68, Po0.001) as already previously shown
(Nakano et al, 1998). At diagnosis, median fibrinogen level of the
entire study population was 627mg dl 1 (range: 196–1200, s.e.m.
15.8). When patients were divided by median fibrinogen level, 87
patients were allocated to the high-fibrinogen group
(4627mg dl 1) and 89 patients were allocated to the low-
fibrinogen group (p627mg dl 1). Table 1 shows patient char-
acteristics according to fibrinogen levels. There was no significant
difference between the high vs low-fibrinogen group with regard to
age, gender or histological subtype, whereas patients in the high-
fibrinogen group were more frequently diagnosed at the late stage
of disease and were more frequently treated by BSC or chemo-
and/or radiotherapy than by multimodality therapy including
macroscopic radical surgery.
Median OS of the entire study population was 13.8 months
(95% CI 11–16.7 months). In univariate survival analyses,
treatment (Po0.001), histology (P¼ 0.001), stage (P¼ 0.012) and
fibrinogen (either as metric factor (Po0.001), grouped by median
(Po0.001) or clinical cutoff (P¼ 0.001)) had significant prognostic
impact on OS, whereas age (neither as metric nor as grouped by
median) and gender showed no prognostic value (as summarised
in Table 2).
Patients receiving multimodality therapy including macroscopic
radical surgery survived significantly longer (OS 30.9 months, CI
12.9–48.9 months) than patients treated by chemo- and/or
radiotherapy alone (OS 12.6 months, CI 8.7–16.5 months,
P¼ 0.001) or those receiving BSC (OS 6.5 months, CI 3.8–9.3
months, Po0.001) as shown in Figure 1A. Patients with the
epithelioid histological subtype had significantly better prognosis
(OS 14.6 months, CI 10.5–18.7 months) when compared with
those with non-epithelioid subtype (OS 6.5 months, CI 2.9–10.1
months, P¼ 0.001, Figure 1B). Furthermore, the late stage of
disease was associated with poor outcome (OS 12.8 months, CI
9.7–15.9 months) when compared with early stage (OS 18.6
months, 0–39.8 months, P¼ 0.012) in univariate survival analyses
(Figure 1C).
Fibrinogen was a prognostic marker when analysed either as a
metric variable (Po0.001), grouped by the clinical cutoff value
(hazard ratio (HR) 2.5, CI 1.4–4.2, P¼ 0.001) or by the median
fibrinogen level of the entire study population (HR 2.1, CI 1.5–3.0,
Po0.001). Accordingly, patients in the low-fibrinogen group
(p627mg dl 1) survived significantly longer (OS 19.1 months,
14.5–23.7 months) than patients in the high-fibrinogen group
(OS 8.5 months, 6.2–10.7 months, Po0.001) (Figure 2A).
In order to clarify whether fibrinogen is an independent
prognostic factor in MPM, we performed multivariate survival
analyses. Therefore, Cox regression was utilised and the model was
adjusted for age (grouped by median age), gender, stage (early vs
late stage), histology (epithelioid vs non-epithelioid MPM),
treatment (BSC vs chemo- and/or radiotherapy vs multimodality
therapy including macroscopic radical surgery) and fibrinogen.
Histological subtype (HR 2.5, CI 1.4–4.2, P¼ 0.001), treatment
Table 1. Patient characteristics and distribution according to median fibrinogen level
High fibrinogen
(4627mgdl1)
Low fibrinogen
(p627mgdl1) All patients
Characteristics Numbers (%) Numbers (%) P-valuea Numbers (%)
Age, years
p64 46 52.9 39 43.8 0.23 85 48.3
464 41 47.1 50 56.2 91 51.7
Sex
Female 17 19.5 21 23.6 0.51 38 21.6
Male 70 80.5 68 76.4 138 78.4
Histology
Epithelioid 68 78.2 78 87.6 0.10 146 83.0
Non-epithelioid 19 21.8 11 12.4 30 17.0
Stageb
Early stage 5 6.9 14 17.9 0.04 19 12.7
Late stage 67 93.1 64 82.1 131 87.3
Treatment
Best supportive care 26 29.9 18 20.2 0.01 44 25.0
Chemo- and/or radiotherapy 44 50.6 34 38.2 78 44.3
Multimodality treatment including radical surgery 17 19.5 37 41.6 54 30.7
aTwo-sided w2-test.
bMissing cases: n¼ 26 (14.8%).
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(BSC: HR 2.5, CI 1.4–4.4, P¼ 0.002, chemo- and/or radiotherapy:
HR 1.7, CI 1.0–2.8, P¼ 0.036, multimodality therapy including
surgery: P¼ 0.009) and fibrinogen (HR 1.8, CI 1.2–2.7, P¼ 0.003)
were found to be independent prognostic factors after multivariate
survival analyses, whereas age, gender and tumour stage had no
independent prognostic impact on OS in our study population as
shown in Table 3.
As fibrinogen showed independent prognostic power in our
retrospective study, we explored the possibility that fibrinogen —
similar to CRP (Ghanim et al, 2012) — could also predict response
to various treatment modalities. We therefore utilised the above
mentioned Cox regression model and calculated the interaction
terms for treatment and fibrinogen. No significant interaction was
found between treatment and median fibrinogen (interaction
P-value for BSC: 0.901, chemo- and/or radiotherapy: 0.816 and for
multimodality therapy: 0.926) excluding a predictive value of
median fibrinogen in our study population. However, using the
75th percentile for grouping the study population, fibrinogen
showed a significant interaction P-value (interaction term 0.034)
indicating that patients with remarkably elevated fibrinogen
(4750mg dl 1) do not benefit from radical surgery within
multimodality therapy when compared with patients receiving
chemo- and/or radiotherapy and BSC. Accordingly, patients above
the 75th percentile receiving multimodality therapy survived
significantly shorter than patients under the 75th percentile also
receiving macroscopic radical surgery within multimodality
therapy (5.3 vs 31.3 months OS, Figure 2B). Thus, circulating
fibrinogen below the cutoff level of 750mg dl 1 was found to be a
predictive biomarker, indicating benefit achieved by surgery as part
of the multimodality treatment regimen.
Finally, we investigated the sensitivity and specificity of plasma
fibrinogen levels in predicting short-term OS and compared its
prognostic power with the CRP levels. Therefore, ROC analysis
was performed and we tested both markers for early mortality
prediction (death before median OS (13.8 months) of the entire
study population was reached). The area under the curve (AUC)
for prognosticating early death was 0.771 and 0.734 for CRP and
fibrinogen, respectively, indicating that both biomarkers had
equally high accuracy for predicting poor outcome in MPM
(Figure 3). We also determined the cutoff point with the highest
Youden index for prognosticating early death. It was found to be
very close to the median fibrinogen level (the highest Youden index
was 0.335 at 623.5mg dl 1 (sensitivity 65.1%, specificity 68.4%). In
turn, the prognostic value at the two different cutoff points was
essentially the same (fibrinogen median (p627mg dl 1) HR 2.1,
CI 1.5–3.0 vs fibrinogen Youden (at 623.5mg dl 1) HR 2.2, CI
1.5–3.1). Considering sensitivity/specificity analysis, median fibri-
nogen level (p627mg dl 1) reached a sensitivity of 63.9% and a
specificity of 68.4% for early death prediction. When using the 75th
percentile (750mg dl 1) as cutoff point, a lower sensitivity of
31.3% but higher specificity of even 82.9% was reached for
Table 2. Univariate survival analyses (n¼176)
Characteristics OS (CI) P-valuea HR (CI)
Age, years
p64 13.7 (10.0–17.4) 0.52 0.90 (0.64–1.25)
464 13.9 (10.3–17.6)
Sex
Female 12.0 (8.2–15.9) 0.54 0.88 (0.58–1.33)
Male 13.9 (10.7–17.2)
Histology
Epithelioid 14.6 (10.5–18.7) o0.01 2.01 (1.31–3.10)
Non-epithelioid 6.5 (2.9–10.1)
Stageb
Early stage 18.6 (0–39.8) 0.01 2.09 (1.17–3.76)
Late stage 12.8 (9.7–15.9)
Treatment
Best supportive care 6.5 (3.8–9.3) o0.01 2.81 (1.75–4.51)
Chemo- and/or radiotherapy 12.6 (8.7–16.5) 2.03 (1.33–3.10)
Multimodality treatment
including radical surgery
30.9 (12.9–48.9) 1
Fibrinogen
High fibrinogen 8.5 (6.2–10.7) o0.01 2.11 (1.49–2.99)
Low fibrinogen 19.1 (14.5–23.7)
Abbreviations: CI¼ confidence interval; HR¼ hazard ratio; OS¼overall survival.
aTwo-sided log-rank test.
bMissing cases: n¼ 26 (14.8%).
100
80
O
ve
ra
ll 
su
rv
iva
l (%
)
60
40
20
20 40 60 80
Months
Best supportive care
Multimodality treatment
Chemo/radiotherapy alone
Epithelioid
Non-epithelioid
Late stage
Early stage
0
0
100
80
O
ve
ra
ll 
su
rv
iva
l (%
)
60
40
20
20 40 60 80
Months
0
0
100
80
O
ve
ra
ll 
su
rv
iva
l (%
)
60
40
20
20 40 60 80
Months
0
0
Figure 1. Overall survival of patients according to treatment regimen
(A), histological subtype (B) and disease stage at the time of diagnosis
(C). Multimodality treatment results in a significant increase in OS
when compared with best supportive care or to chemo- and/or
radiotherapy alone (Po0.001). Epithelioid mesothelioma confers a
better prognosis in terms of OS over non-epithelioid mesothelioma
(P¼ 0.001). Mesothelioma patients diagnosed at early stage have
significantly increased OS when compared with late-stage (P¼0.012).
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predicting early death in MPM. In contrast, CRP (cutoff
1mg dl 1) reached a very high sensitivity of 93.9%, whereas the
specificity was 46.8% only.
DISCUSSION
Here we report, to the best of our knowledge for the first time, that
the plasma fibrinogen level at the time of diagnosis is an
independent prognostic biomarker in MPM patients. More
importantly, fibrinogen was found to be a predictive biomarker
in MPM, indicating survival benefit achieved by macroscopic
radical surgery within multimodality treatment regimens. Patients
with diagnostic fibrinogen levels above the 75th percentile did not
benefit from macroscopic complete resection within multimodality
treatment protocols in our retrospective multicenter study.
Recently, the survival benefit of MCR by EPP in MPM patients
has been questioned (Treasure et al, 2011). However, in the past
decades superior survival was described in retrospective studies for
patients receiving MCR especially in subgroups able to complete
trimodality therapy (Krug et al, 2009). These findings highlight the
urgent need for better patient selection criteria and predictive
biomarkers especially with regard to MCR within multimodality
treatment regimens to offer the opportunity of life prolonging
radical treatments on the one hand and protecting patients from
futile and harmful therapy on the other hand (Scherpereel et al,
2010; Stahel et al, 2010; Cao et al, 2011). Recently we showed, that
pretreatment serum CRP levels at the time of diagnosis can predict
survival benefit, achieved by MCR within multimodal therapy.
Patients with normal CRP receiving multimodality therapy had a
superior median OS of 35.9 months (95% CI 7.7–11.7) when
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Figure 2. The prognostic and predictive impact of plasma fibrinogen levels in MPM. (A) Patients with low fibrinogen (below median,
p627mgdl1) demonstrate superior OS as opposed to patients with high levels (4627mgdl 1). (B) The Kaplan–Meier survival analysis
demonstrated the predictive impact of fibrinogen at the cutoff of 750mgdl 1 (75th percentile). Patients with higher fibrinogen levels than
the 75th percentile/750mgdl 1 do not benefit from multimodality treatment including macroscopic radical surgery when compared with
chemo- and/or radiotherapy alone.
Table 3. Cox regression model adjusted for patient characteristics of all
patients with available complete data for model adjustment (n¼ 150,
85.2% of the total study population)
Characteristics
Adjusted
HR for death 95% CI
Adjusted
P-value
Age, years
p64 0.87 0.60–1.27 0.47
464 1
Sex
Female 1.22 0.74–2.02 0.44
Male 1
Histology
Epithelioid 1 o0.01
Non-epithelioid 2.45 1.43–4.21
Stage
Early stage 1 0.25
Late stage 1.52 0.75–3.10
Treatment
Best supportive care 2.45 1.38–4.35 o0.01
Chemo- and/or radiotherapy 1.70 1.04–2.80 0.04
Multimodality treatment
including radical surgery
1 o0.01
Fibrinogen
High fibrinogen 1.81 1.23–2.65 o0.01
Low fibrinogen 1
Abbreviations: CI¼ confidence interval; HR¼ hazard ratio.
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Figure 3. The accuracy of the plasma fibrinogen level and the CRP
level to predict short-term OS in MPM. Receiver Operating
Characteristic curve considering early death prediction (death before
median overall survival of 13.8 months) showed an AUC of 0.734 and
0.771 for fibrinogen and CRP, respectively. The dotted lines mark the
highest Youden index for fibrinogen (Youden index¼0.335,
sensitivity¼ 0.651, specificity¼ 0.684, cutoff at 623.5mgdl 1).
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compared with patients with elevated CRP receiving multimodality
therapy (OS 7.9 months, 95% CI 4.9–10.8) (Ghanim et al, 2012). In
other words: patients with normal CRP receiving radical surgery
within multimodality therapy had more than two-fold longer OS
time when compared with the patients included in the Mesothe-
lioma and Radical Surgery (MARS) feasibility study receiving EPP
(Treasure et al, 2011). Similar to our previous findings (Ghanim
et al, 2012), we show in our present study, that patients with
diagnostic fibrinogen levels above the 75th percentile receiving
multimodality therapy survived significantly shorter than patients
under the 75th percentile also treated by multimodality therapy
(5.3 vs 31.3 months OS, Figure 2).
Similar to the study of Seebacher et al (2010) on endometrial
cancer and to the study of Polterauer et al (2009 on ovarian cancer,
we found an association of elevated diagnostic fibrinogen level with
the advanced stage of disease. However, it is not clear yet, whether
elevated fibrinogen in late-stage cancer patients is a result of
enhanced immune response against the higher tumour load or due
to increased autocrine growth stimulation (Polterauer et al, 2009;
Seebacher et al, 2010). In accordance with other studies on thoracic
malignancies, there was a strong positive correlation between
fibrinogen and CRP levels (Nakano et al, 1998; Gulen et al, 2012).
These findings suggest that increased fibrinogen and CRP levels in
MPM patients are a consequence of similar pro-inflammatory
mechanisms as it has been already proposed by Nakano et al
(1998). Furthermore, sensitivity and specificity analysis in our
study indicated that both CRP and fibrinogen are promising
biomarkers in MPM. The combination of the two markers would
result in increased accuracy as CRP has a higher sensitivity and
fibrinogen is characterised by higher specificity in predicting early
death in MPM.
To date, it is not understood whether fibrinogen and its
prognostic power in cancer patients is only a bystander
characteristic or fibrinogen itself has an active role during cancer
progression by promoting cell adhesion, proliferation, angiogenesis
and cell migration (Laurens et al, 2006). Furthermore, the
biological background of fibrinogen’s prognostic and predictive
power also remains to be unveiled.
In summary, in this study we were able to show for the first
time that fibrinogen is an independent prognostic biomarker in
MPM patients. More importantly, we found a significant
interaction between diagnostic fibrinogen levels and treatment
modality, indicating, that MPM patients with remarkably elevated
fibrinogen levels do not benefit from aggressive multimodality
therapy including MCR. However, further independent investiga-
tions and future prospective studies are needed to fully explore
the potential of these markers in MPM. In the past few years, a set
of clinically already available biomarkers – including CRP and
fibrinogen – has emerged that could (cost) effectively support the
therapeutic decision making process in cancer patients in
addition to their classical (inflammatory/coagulation system)
indications.
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